Kit Approved by AOAC International and certified NF VALIDATION by AFNOR Certification

HERCULES, Calif. — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of EZ-Check Salmonella spp. Kit, a rapid qualitative test for detection of Salmonella spp. in a variety of food and environmental samples. The test has been validated by AOAC International (under the AOAC Research Institute Performance Tested Method Program) and certified NF VALIDATION by AFNOR Certification.

Bio-Rad’s ready-to-use EZ-Check Salmonella spp. Kit uses PCR to deliver streamlined workflows with rapid time to results, featuring multiplex amplification of the target pathogen and an internal control to prevent false negatives, while the duplex detection system enhances accuracy and simplifies reaction set up.

The EZ-Check Salmonella spp. Kit has been validated by both international certification organizations on parameters such as robustness, product consistency, stability, inclusivity and exclusivity, and matrix studies. In addition, Bio-Rad’s iQ-Check Free DNA Removal Solution was validated as part of the workflow for testing all matrices included in the validation scope.

Detection of Salmonella remains a critical priority for food manufacturers as contamination can lead to severe health risks and costly product recalls. The EZ-Check Salmonella spp. Kit enables food producers to enhance quality control processes, minimizing the risk of outbreaks while ensuring compliance with global food safety standards.

“The increase in reported Salmonella-related infections in recent years has led to a greater demand for robust, accurate testing solutions to prevent outbreaks and protect consumers. Our portfolio of EZ-Check real-time PCR tests provide a simple workflow for food pathogen testing, delivering reliable results with improved operational and cost efficiency,” said Franck Edouard, Senior Marketing Director, Food Science Division, Bio-Rad Laboratories. “The new Salmonella EZ-Check Kit, with international recognition, solidifies our position as leaders in the food safety industry, providing validated technologies for detection of pathogens in food and environmental products.”

For more information on Bio-Rad’s EZ-Check Kits, visit bio-rad.com/EZCheck.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,500 employees, and $2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.

Forward-Looking Statements

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include risks relating to our international operations, global economic and geopolitical conditions, tariffs or other trade barriers, reductions in government funding or capital spending of our customers, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.